7UM0.F Zelluna ASA

Healthcare Biotechnology Frankfurt Exchange
1.45 EUR
Close of Nov 11, 2026
0.6810 2.98
Market cap
EUR 43.1M
P/E
-
P/B
5.28x
ROE
-106.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 7UM0.F undervalued?

Graham number

The Graham number of Zelluna ASA cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Zelluna ASA fundamental analysis

No fundamental analysis for Zelluna ASA yet.

Zelluna ASA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Zelluna ASA

Zelluna ASA, a clinical-stage biotechnology company, engages in the development of T-cell receptor guided natural killer cell therapies in Norway. It develops ZI-MA4-1 which is in Phase I clinical trial for the treatment of non-small cell lung cancer, ovarian, and head and neck synovial sarcoma; ZI-KL1-1 which is in preclinical trial for the treatment of breast, gastric, lung, pancreatic, and cervix cancers; and ZI-PR-1 which is in discovery stage for the treatment of solid …

Full company profile